Rate of TXB₂ production in healthy subjects (A) and urinary excretion rates of 11-dehydro-TXB₂ in clinical settings at high cardiovascular risk. (A) The metabolic fate of TXA₂ in vivo and the calculated rate of its production in healthy subjects on the basis of TXB₂ infusions and measurement of its major urinary metabolite.^11,47  (B) Mean (± standard deviation) or median (interquartile range) urinary excretion rates of 11-dehydro-TXB₂ in clinical settings characterized by high cardiovascular risk.^7,8,12-19  CHD, coronary heart disease; PCI, percutaneous coronary intervention; T2DM, type 2 diabetes mellitus.